Update diagnostische Bildgebung des dopaminergen Systems

Zusammenfassung

Die Arbeit gibt ein Update zu dem Einsatz der SPECT- und PET-Bildgebung des prä- und postsynaptischen dopaminergen Systems bei klinisch wichtigen Bewegungsstörungen. Die typischen Untersuchungsbefunde bei neurodegenerativen Parkinson-Syndromen (idiopathisch und nicht-idiopathisch), symptomatischen Parkinson-Syndromen und wichtigen Differentialdiagnosen werden beschrieben. Es wird auf den klinisch praktischen Stellenwert der Methoden eingegangen, deren diagnostische Aussagekraft und Limitationen bewertet, das Thema standardisierter Auswertungen angesprochen und auf die in Leitlinien festgehaltenen Einsatzbereiche Bezug genommen.

Abstract

This paper gives an update on the use of SPECT- and PET-imaging of the pre- and postsynaptic dopaminergic system in the diagnostic work-up of patients with clinically important movement disorders. Typical findings in neurodegenerative parkinsonism (idiopathic and non-idiopathic), in secondary parkinsonism and major differential diagnoses are described. The current clinical impact of the methods with their diagnostic accuracy and limitations are discussed, standardized evaluation methods mentioned, and the role of dopaminergic imaging in current guidelines addressed.

Schlüsselwörter

Single-Photon-Emissions-Computertomografie - Positronen-Emissions-Tomografie - Parkinson-Syndrome - dopaminerges System - Dopamintransporter - Dopaminrezeptoren

Keywords

Single-photon-emission-tomography - positron-emission tomography - movement disorders - dopaminergic system - dopamine transporter - dopamine receptor

Publication History

Article published online:
02 December 2022

• Literaturverzeichnis

• 1 Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28: 99-102 DOI: 10.1093/ageing/28.2.99. (PMID: 10350403)
• 2 Hughes AJ, Daniel SE, Ben-Shlomo Y. et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-870 DOI: 10.1093/brain/awf080. (PMID: 11912118)
• 3 Marshall VL, Reininger CB, Marquardt M. et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24: 500-508 DOI: 10.1002/mds.22108.
• 4 Seibyl J, Russell D, Jennings D. et al. The molecular basis of dopaminergic brain imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012; 56: 4-16 (PMID: 22460156)
• 5 Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012; 56: 68-82 (PMID: 22460161)
• 6 Varrone A, Halldin C. Molecular imaging of the dopamine transporter. J Nucl Med 2010; 51: 1331-1334 DOI: 10.2967/jnumed.109.065656. (PMID: 20720060)
• 7 Brooks DJ. Assessment of Parkinson's disease with imaging. Parkinsonism Relat Disord 2007; 13: S268-275 DOI: 10.1016/S1353-8020(08)70015-4. (PMID: 18267249)
• 8 Morbelli S, Esposito G, Arbizu J. et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging 2020; 47: 1885-1912 DOI: 10.1007/s00259-020-04817-8. (PMID: 32388612)
• 9 Tatsch K, Buchert R, Bartenstein P. et al. SPECT-Untersuchungen mit dem I-123-markierten Dopamintransporter-Liganden FP-CIT (DaTSCANTM) DGN-Handlungsempfehlung (S1-Leitlinie). Nuklearmedizin 2019; 58: 5-16 DOI: 10.1055/a-0807-8137. (PMID: 30769368)
• 10 Neill M, Fisher JM, Brand C. et al. Practical Application of DaTQUANT with Optimal Threshold for Diagnostic Accuracy of Dopamine Transporter SPECT. Tomography 2021; 7: 980-989 DOI: 10.3390/tomography7040081. (PMID: 34941653)
• 11 Schmitz-Steinkrüger H, Lange C, Apostolova I. et al. Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT. Eur J Nucl Med Mol Imaging 2021; 48: 1445-1459 DOI: 10.1007/s00259-020-05085-2. (PMID: 33130960)
• 12 Wenzel M, Milletari F, Krüger J. et al. Automatic classification of dopamine transporter SPECT: deep convolutional neural networks can be trained to be robust with respect to variable image characteristics. Eur J Nucl Med Mol Imaging 2019; 46: 2800-2811 DOI: 10.1007/s00259-019-04502-5.. (PMID: 31473800)
• 13 Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med 2013; 54: 1331-8 DOI: 10.2967/jnumed.112.105379. (PMID: 23864718)
• 14 Booth TC, Nathan M, Waldman AD. et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. AJNR Am J Neuroradiol 2015; 36: 229-35 DOI: 10.3174/ajnr.A3970. (PMID: 24904053)
• 15 Marek KL, Seibyl JP, Zoghbi SS. et al. 123I. Neurology 1996; 46: 231-237 DOI: 10.1212/wnl.46.1.231. (PMID: 10348466)
• 16 Palermo G, Ceravolo R. Molecular Imaging of the Dopamine Transporter. Cells 2019; 8: 872 DOI: 10.3390/cells8080872. (PMID: 31405186)
• 17 Pirker W, Djamshidian S, Asenbaum S. et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17: 45-53 DOI: 10.1002/mds.1265. (PMID: 11835438)
• 18 Marek K, Seibyl J, Eberly S. et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82: 1791-1797 DOI: 10.1212/WNL.0000000000000424. (PMID: 24759846)
• 19 Sixel-Döring F, Liepe K, Mollenhauer B. et al. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: a critical assessment of 125 cases. J Neurol 2011; 258: 2147-2154 DOI: 10.1007/s00415-011-6076-z. (PMID: 21547379)
• 20 la Fougere C, Pöpperl G, Levin J. et al. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 2011; 51: 581-587 DOI: 10.2967/jnumed.109.071811. (PMID: 20237026)
• 21 Tatsch K. Extrapyramidal syndromes: PET and SPECT. Neuroimaging Clin N Am 2010; 20: 57-68 DOI: 10.1016/j.nic.2009.08.017. (PMID: 19959018)
• 22 Booth TC, Nathan M, Waldman AD. et al. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 2. AJNR Am J Neuroradiol 2015; 36: 236-44 DOI: 10.3174/ajnr.A3971. (PMID: 24924549)
• 23 Oliveira FPM, Walker Z, Walker RWH. et al. 123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases. J Neurol Neurosurg Psychiatry 2021; DOI: 10.1136/jnnp-2020-324606.
• 24 Suzuki M, Desmond TJ, Albin RL. et al. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol 2002; 51: 767-771 DOI: 10.1002/ana.10186. (PMID: 12112084)
• 25 O'Brien JT, Colloby S, Fenwick J. et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61: 919-925 DOI: 10.1001/archneur.61.6.919. (PMID: 15210531)
• 26 McKeith I, O'Brien J, Walker Z. et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305-313 DOI: 10.1016/S1474-4422(07)70057-1. (PMID: 17362834)
• 27 Papathanasiou ND, Boutsiadis A, Dickson J. et al. Diagnostic accuracy of (1)(2)(3)I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 2012; 18: 225-229 DOI: 10.1016/j.parkreldis.2011.09.015. (PMID: 21975260)
• 28 McKeith IG, Boeve BF, Dickson DW. et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 2017; 89: 88-100 DOI: 10.1212/WNL.0000000000004058.. (PMID: 28592453)
• 29 Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging 2012; 56: 17-26 (PMID: 22460157)
• 30 Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D. et al. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. Eur J Nucl Med Mol Imaging 2010; 37: 556-564 DOI: 10.1007/s00259-009-1289-4. (PMID: 19862520)
• 31 Tinazzi M, Antonini A, Bovi T. et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol 2009; 256: 910-915 DOI: 10.1007/s00415-009-5039-0. (PMID: 19252795)
• 32 Uchida H, Suzuki T. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications. J Clin Psychopharmacol 2014; 34: 728-735 DOI: 10.1097/JCP.0000000000000065. (PMID: 24781442)
• 33 Gaig C, Marti MJ, Tolosa E. et al. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord 2006; 21: 1994-1998 DOI: 10.1002/mds.21062. (PMID: 16941463)
• 34 Barthel H, Hermann W, Kluge R. et al. Concordant pre- and postsynaptic deficits of dopaminergic neurotransmission in neurologic Wilson disease. AJNR Am J Neuroradiol 2003; 24: 234-238 (PMID: 12591639)
• 35 Gerschlager W, Bencsits G, Pirker W. et al. 123I. Mov Disord 2002; 17: 518-523 DOI: 10.1002/mds.10092. (PMID: 12112200)
• 36 Zijlmans JC. The role of imaging in the diagnosis of vascular parkinsonism. Neuroimaging Clin N Am 2010; 20: 69-76 DOI: 10.1016/j.nic.2009.08.006.. (PMID: 19959019)
• 37 Contrafatto D, Mostile G, Nicoletti A. et al. (123) I. Acta Neurol Scand 2012; 126: 12-16 DOI: 10.1111/j.1600-0404.2011.01583.x.. (PMID: 33411199)
• 38 Benamer TS, Patterson J, Grosset DG. et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000; 15: 503-510 DOI: 10.1002/1531-8257(200005)15:33.0.CO;2-V. (PMID: 28470733)
• 39 Camardese G, Di Giuda D, Di Nicola M. et al. Imaging studies on dopamine transporter and depression: A review of literature and suggestions for future research. J Psych Res 2014; 51: 7-18 DOI: 10.1016/j.jpsychires.2013.12.006. (PMID: 24433847)
• 40 van Eimeren T, Claßen J, Drzezga A. et al. Empfehlung zum differenzierten Einsatz nuklearmedizinischer Diagnostik bei Parkinson-Syndromen. Fortschr Neurol Psychiatr 2020; 88: 609-619 DOI: 10.1055/a-1207-0515. (PMID: 32957144)